PDI signs four-year deal with Novartis

Share this article:
Contract sales firm PDI signed a four-year agreement with Novartis to deploy a field force promoting Elidel, a second-line eczema treatment for patients older than 2 years, according to Kim Golodetz, a spokesperson for PDI. 

The deal calls for deployment of “approximately 100 full-time equivalent sales representatives who will call upon physicians nationwide,” a PDI statement said. 

After losing contracts with GlaxoSmithKline and Sanofi-Aventis in 2006, PDI rebounded with a “top-five pharmaceutical company” contract in 2007.  

In February, the company named Peter Tilles president of its TVG marketing research and consulting unit.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.